Humulin M3 (30/70) Cartridge (Insulin Human)

Humulin M3 (30/70) Cartridge is indicated for the management of blood glucose in adults with diabetes.

• Type 1 diabetes mellitus requiring basal and prandial insulin.
• Type 2 diabetes mellitus when a mixed insulin regimen is appropriate.
• Patients who need a convenient single daily injection to cover both fasting and post‑meal glucose.
• Use as part of a comprehensive diabetes care plan that includes diet, exercise, and self‑monitoring of blood glucose.
• Adjustments may be required during periods of illness, changes in physical activity, or when using other glucose‑lowering agents.
• May be used in combination with rapid‑acting insulin analogues for finer mealtime glucose control when prescribed.

• Humulin M3 (30/70) contains human insulin that binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling pathways, including the PI3‑K/Akt cascade, which promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake in muscle and adipose tissue. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production.

Adverse reactions to Humulin M3 (30/70) may vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, shakiness, confusion, or dizziness due to low blood glucose.
• Injection‑site reactions such as redness, swelling, bruising, or itching at the site of subcutaneous administration.
• Lipodystrophy, characterized by localized accumulation or loss of subcutaneous fat with repeated injections.
• Weight gain, often modest, associated with improved glycemic control and insulin’s anabolic effects.

Serious

• Severe hypoglycemia that may cause loss of consciousness, seizures, or require assistance from another person.
• Allergic reactions ranging from urticaria and angioedema to life‑threatening anaphylaxis.
• Fluid retention leading to peripheral edema or worsening of pre‑existing heart failure.
• Hypersensitivity pulmonary reactions, including bronchospasm or respiratory distress.

When prescribing Humulin M3 (30/70), clinicians should consider several precautionary measures to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose changes, or periods of altered diet or activity.
• Use caution in patients with a history of severe hypoglycemia or hypoglycemia unawareness.
• Evaluate for cardiovascular disease; fluid retention may exacerbate heart failure.
• Educate patients on proper injection technique to reduce risk of lipodystrophy.
• Consider pregnancy status; insulin requirements may change, and safety data are limited.

Humulin M3 (30/70) can interact with other medicines that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment, which may cause severe hypoglycemia.
• High‑dose beta‑blockers that mask hypoglycemia symptoms.
• Systemic corticosteroids that markedly increase blood glucose and may require insulin dose escalation.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which can potentiate hypoglycemia.
• ACE inhibitors or ARBs, as they may enhance insulin sensitivity.
• Thiazide diuretics, which can raise blood glucose levels.
• Alcohol consumption, which can cause unpredictable glucose fluctuations.